Novo Nordisk shares surged as much as 8.6% in early Copenhagen trading, marking their biggest gain this year. The Danish pharmaceutical giant's stock rebounded after Hims & Hers Health announced it would stop offering a copycat version of the Wegovy weight-loss pill. The move came just a day after the US Food and Drug Administration pledged to crack down on unauthorized weight-loss drug copies.

Hims & Hers made the announcement on X Saturday, reversing a strategy that had threatened Novo Nordisk's market dominance in the lucrative GLP-1 weight-loss drug segment. The FDA's commitment to enforcement against copycat medications provided regulatory backing that strengthened Novo Nordisk's position. This development represents a significant win for the pharmaceutical giant, which had seen its stock price decline in recent weeks amid growing competition concerns.

The market reaction underscores investor confidence in Novo Nordisk's intellectual property protection and the durability of its weight-loss drug franchise. With Wegovy sales driving substantial revenue growth, maintaining exclusivity remains critical for the company's valuation and future earnings potential. The swift stock recovery demonstrates how regulatory actions can dramatically impact pharmaceutical market dynamics and competitive positioning.